Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:49 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma
NCT00520533 · Ludwig Institute for Cancer Research · PHASE1 · terminated · last registry update 2022-10-12 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Closed prematurely due to toxicity” | – | Registry record, Ludwig Institute for Cancer Research |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CSF1R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-10-10Results posted on the registry: M.D. Anderson Cancer Center, Bevacizumab + Emactuzumab (NCT02923739)
- 2023-09-21Results posted on the registry: Dartmouth-Hitchcock Medical Center, Sunitinib + Temsirolimus (NCT01517243)
- 2023-08-18Results posted on the registry: Yale University, APX005M + Cabiralizumab (NCT03502330)
- 2023-08-01Results posted on the registry: Daiichi Sankyo, Quizartinib (NCT04473664)
- 2023-07-07Phase 3 first posted: GB002, Inc., Placebo + Seralutinib (NCT05934526)
- 2023-04-27Results posted on the registry: Daiichi Sankyo Co., Ltd., Pexidartinib (NCT04488822)
- 2023-04-11Results posted on the registry: National Cancer Institute (NCI), AZD6244 + MK-2206 (NCT01306045)
- 2023-04-11Results posted on the registry: Nektar Therapeutics, bempegaldesleukin + sunitinib (NCT03729245)
- 2023-04-11Also stopped (terminated): Nektar Therapeutics, bempegaldesleukin + sunitinib (NCT03729245)
- 2023-03-31Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Durvalumab + SNDX-6352 (NCT04301778)
- 2023-03-21Results posted on the registry: Novartis Pharmaceuticals, Pazopanib (NCT03200717)
- 2023-02-17Phase 3 first posted: Deciphera Pharmaceuticals, LLC, Ripretinib + Sunitinib (NCT05734105)
- 2023-01-11Results posted on the registry: Daiichi Sankyo, Quizartinib dihydrochloride + 14C-Quizartinib solution for infusion (NCT04796831)
- 2023-01-10Phase 3 first posted: Exelixis, XL092 + Nivolumab (NCT05678673)
- 2022-10-05Results posted on the registry: Daiichi Sankyo, Chemotherapy + Quizartinib (NCT02668653)
- 2022-09-28Also stopped (terminated): Rutgers, The State University of New Jersey, Pazopanib + Paclitaxel (NCT01407562)
- 2022-09-15Also stopped (terminated): Prof. Dr. Richard F Schlenk, MRD-triggered arm + Prophylactic Arm (NCT03989713)
- 2022-09-02Results posted on the registry: National Cancer Institute (NCI), Cabozantinib S-malate + Crizotinib (NCT02761057)
- 2022-08-30Also stopped (withdrawn): Federation Francophone de Cancerologie Digestive, FOLFIRI regimen + fluorouracil (NCT00936832)
- 2022-08-23Also stopped (terminated): National Cancer Institute (NCI), Pazopanib + Pazopanib Hydrochloride (NCT02601209)
- 2022-08-22Results posted on the registry: Mendus, Intuvax (INN: ilixadencel) + Sunitinib (NCT02432846)
- 2022-08-19Results posted on the registry: Fox Chase Cancer Center, pazopanib hydrochloride (NCT01462630)
- 2022-08-15Also stopped (terminated): Roswell Park Cancer Institute, panobinostat + everolimus (NCT01582009)
- 2022-07-28Phase 3 first posted: RayzeBio, Inc., RYZ101 + Everolimus (NCT05477576)
- 2022-07-22Results posted on the registry: Syndax Pharmaceuticals, SNDX-6352 + Placebo (NCT04415073)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision